You are viewing: China Cell Expansion Market analysis
Part of: Cell Expansion Market (Global)

The China Cell Expansion Market was valued at $24 Million in 2024 and projected to reach to $49.4 Million by 2029, representing a compound annual growth rate of CAGR 15.5%. China's cell expansion market is poised for sustained growth through 2029, driven by escalating investments in regenerative medicine and cell-based therapeutics.

China Cell Expansion Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Cell Expansion Market Trends and Insights

  • This expansion reflects China's increasing investment in regenerative medicine, biopharmaceutical manufacturing, and advanced cell therapy platforms.
  • China's growing healthcare infrastructure and government support for biotechnology innovation are driving accelerated adoption of cell expansion technologies across research institutions and commercial facilities. The 15.5% compound annual growth rate in China significantly outpaces global trends, underscoring the country's strategic focus on cellular therapeutics and personalized medicine.
  • China's expanding biomanufacturing capacity and rising demand for autologous and allogeneic cell therapies are key catalysts for market expansion through 2029.
  • Investment in GMP-compliant cell expansion facilities and automation technologies positions China as a critical hub for cell therapy development in the Asia Pacific region..

Key Market Statistics

  • CAGR (2024-2029) CAGR 15.5%
  • Market Size, 2024 ~USD 24 Million
  • Forecast, 2029 ~USD 49.4 Million
  • Country China

China Cell Expansion Market Overview

Rapid Market Expansion :

China's cell expansion market is growing at 15.5% CAGR, outpacing the global rate of 13.3%, driven by increased biopharmaceutical manufacturing and regenerative medicine adoption across major cities.

Government Biotech Support :

Chinese government initiatives and substantial R&D investments in biotechnology are accelerating cell therapy platform development and creating favorable regulatory pathways for advanced cell expansion technologies.

Healthcare Infrastructure Growth :

Expanding hospital networks and specialized cell therapy centers in tier-1 and tier-2 cities are establishing robust demand for cell expansion systems and consumables across China's healthcare ecosystem.

Manufacturing Scale-Up :

Chinese biopharmaceutical manufacturers are increasingly adopting automated cell expansion solutions to meet domestic demand and position themselves for international CAR-T and stem cell therapy exports.

China Cell Expansion Market Dynamics

  • The market's 15.5% CAGR reflects strong government backing for biotechnology innovation and the rapid expansion of manufacturing capabilities across major pharmaceutical hubs.
  • Increasing clinical applications in oncology and degenerative disease treatment are creating substantial demand for advanced cell culture and expansion technologies. The Chinese market benefits from a large patient population, rising healthcare spending, and strategic positioning within global biopharmaceutical supply chains.
  • Domestic companies are rapidly scaling production capacity to support both domestic cell therapy adoption and export opportunities.
  • Continued regulatory streamlining and technology transfer initiatives are expected to further accelerate market penetration and drive competitive innovation in cell expansion platforms..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • SANOFI
    • NOVARTIS
    • Pfizer Inc.

      Key Takeaways

      • China's cell expansion market will nearly double from $24.0M (2024) to $49.4M (2029), driven by 15.5% CAGR growth.
      • China's government support for biotechnology and regenerative medicine is accelerating cell therapy commercialization and manufacturing scale-up.
      • China's biomanufacturing infrastructure investments position the country as a leading cell therapy production hub in Asia Pacific.
      • China's rising demand for personalized and autologous cell therapies is fueling adoption of advanced cell expansion technologies.

      Cell Expansion Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment MEDIA (Type)
      Forecast Period 2024–2029
      Growth Rate CAGR of 13.3% from 2024 to 2029
      Largest Segment CONSUMABLES (Product)
      Market Size Base Year (Billions) ~USD 14.3 (2024)
      Revenue Forecast (Billions) ~USD 26.7 (2029)
      Segments Covered Product, Type, Usage

      China Cell Expansion Market Report Segmentation

      3 segment dimensions are covered across the global market.

      By Product

      • Consumables
      • Equipment

      By Type

      • Automated Cell Expansion Systems
      • Bioreactors
      • Cell Expansion Bags
      • Cell Factory Systems/Cell Stacks
      • Chemically Defined Media
      • Classical Media & Salts
      • Flasks
      • Hollow Fiber Bioreactors
      • Media
      • Microcarrier Bioreactors
      • Multiwell Plates
      • Other Bioreactors
      • Other Cell Expansion Equipment
      • Other Consumables
      • Other Media Types
      • Petri Dishes
      • Reagents
      • Roller/Roux Bottles
      • Sera
      • Serum-Free Media
      • Specialty Media
      • Stem Cell Culture Media
      • Suspension-Based Independent Bioreactors
      • Vessels

      By Usage

      • Conventional Bioreactors
      • Single-Use Bioreactors

      CHINA: CELL EXPANSION MARKET, BY END USER, 2022–2029

      Segment20222023202420252026202720282029CAGR (%)
      HOSPITALS & DIAGNOSTIC LABORATORIES127.7145.3166.6191.9221.8256.5296.5345.115.7
      OTHER END USERS91.6105121.4140.9164.2191.4223261.616.6
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES392.9452.8525.7613.4718.3841.39851161.217.2
      RESEARCH & ACADEMIC INSTITUTES166.1187.8213.9244.9281.3323.1371428.814.9
      TOTAL778.4890.91027.61191.11385.71612.21875.52196.716.4

      Target Audience

      • Biopharmaceutical Manufacturers : Chinese and international biotech companies need detailed market data to assess manufacturing expansion opportunities, identify competitive threats, and optimize cell expansion technology investments for domestic and export markets.
      • Cell Therapy Developers : CAR-T, stem cell, and regenerative medicine companies require China-specific market intelligence to evaluate clinical adoption rates, manufacturing partnerships, and commercialization timelines in this high-growth region.
      • Equipment & Technology Providers : Manufacturers of cell expansion systems, bioreactors, and consumables need market segmentation data to identify customer segments, pricing strategies, and distribution channels within China's rapidly evolving biotech landscape.
      • Healthcare Investors & PE Firms : Investment professionals targeting Chinese biotech and regenerative medicine sectors require validated market forecasts and growth drivers to evaluate portfolio companies, fund allocation, and exit opportunities.
      • Healthcare Policy & Regulatory Bodies : Government agencies and healthcare administrators need market data to inform biotech policy, manufacturing incentives, clinical trial frameworks, and strategic planning for cell therapy integration into China's healthcare system.

      Key Companies in the China Cell Expansion Market

      CompanyHQOwnershipStrongest segments
      PATHEON INCNetherlandsPrivate CompanyDrug product services (finished dosage manufacturing and packaging),Pharmaceutical development services,Drug substance services (API and biologics),
      ALLERGAN PLCIrelandPrivate CompanyUS Specialized Therapeutics (incl. Medical Aesthetics & Eye Care),US General Medicine (GI, CNS, Women’s Health, Anti-infectives),International (All Therapeutic Areas),
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media,Immunological and serological reagents,
      MAXCYTE, INCUnited StatesPublic CompanyExPERT GTx and STx instruments,ExPERT ATx and VLx instruments,Processing assemblies (PAs) and consumables,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing hardware, consumables, services),Life Sciences (instruments, genomics, automation, microscopy),Diagnostics (clinical instruments, consumables, software, services),
      MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, equipment),
      SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical instruments and PAT (BLI, cytometry, live-cell imaging, SPR, data analytics),Lab products and services (filtration, purification, lab water, weighing, pipettes, microbiological testing),
      CORNING INCORPORATEDUnited StatesPublic CompanyOptical Communications (fiber, cable, hardware, connectivity),Display Technologies (LCD and OLED glass substrates),Specialty Materials (mobile device glass, optics, wafers, shielding),
      LONZASwitzerlandPublic CompanyIntegrated Biologics (mammalian and drug product platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs and bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
      TERUMO CORPORATIONJapanPublic CompanyCardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company,
      EPPENDORF SEGermanyPrivate CompanyLiquid handling instruments and automation,Separation, PCR, and cold storage instrumentation,Consumables (tubes, tips, plates, plastics),
      FUJIFILM CORPORATIONJapanPublic CompanyHealthcare (medical systems, CDMO, pharma, regenerative medicine, cosmetics/supplements),Electronics (display, semiconductor, image sensor and functional materials, storage, industrial equipment),Business Innovation (office equipment, document solutions, graphic communications, inkjet),
      BIO-TECHNEUnited StatesPublic CompanyProtein Sciences (reagents and proteomic tools),Diagnostics and Spatial Biology,
      REPLIGEN CORPORATIONUnited StatesPublic CompanyChromatography systems, OPUS columns, resins and ligands,Filtration and perfusion (XCell ATF, TangenX, KrosFlo, TFDF, ProConnex),Process analytics and PAT (PATsmart, SoloVPE, ZipChip, REBEL),
      GETINGE ABSwedenPublic CompanyAcute Care Therapies (ECMO, ventilation, monitoring, ICU infrastructure, drainage),Surgical Workflows (OR tables, lights, anesthesia, OR integration, sterile supply management),Life Science (low-temperature sterilization, biocontainment, terminal sterilization, isolation, bioprocess solutions),
      BDUnited StatesPublic CompanyMedical Essentials (syringes, needles, IV and vascular access, sharps, enteral),Connected Care (infusion systems, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, pharma solutions),
      PERKINELMER INC.United StatesPublic CompanyDiagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science reagents and research tools,Instruments and imaging systems,

      PATHEON INC

      Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology sector.

      ALLERGAN PLC

      Allergan PLC is an Ireland-incorporated private company founded in 1983 with 17,400 employees, operating in the pharmaceutical and specialty healthcare industry.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a Japanese public company founded in 1939 with 696 employees, engaged in chemical and diagnostic product manufacturing.

      MAXCYTE, INC

      MaxCyte, Inc is a United States-based public company founded in 1998 with 91 employees, focused on cell engineering and life sciences technology.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.

      DANAHER CORPORATION

      Danaher Corporation is a United States public company founded in 1969 with 59,000 employees, operating across diversified industrial and life sciences sectors.

      MERCK KGAA

      Merck KGaA is a German public company founded in 1668 with 59,077 employees, operating as a global pharmaceutical, chemical, and life sciences enterprise.

      SARTORIUS AG

      Sartorius AG is a German public company founded in 1870 with 14,242 employees, specializing in laboratory and bioprocess equipment and services.

      CORNING INCORPORATED

      Corning Incorporated is a United States public company founded in 1851 with 67,200 employees, manufacturing specialty glass and advanced materials for multiple industries.

      LONZA

      Lonza is a Swiss public company founded in 1897 with 20,000 employees, providing pharmaceutical and biotechnology manufacturing and life sciences solutions.

      TERUMO CORPORATION

      Terumo Corporation is a Japanese public company founded in 1921 with 30,591 employees, specializing in medical devices and blood management products.

      EPPENDORF SE

      Eppendorf SE is a German private company founded in 1945 with 4,358 employees, manufacturing laboratory equipment and consumables for life sciences research.

      FUJIFILM CORPORATION

      Fujifilm Corporation is a Japanese public company founded in 1934 with 73,526 employees, operating across imaging, healthcare, and materials technology sectors.

      BIO-TECHNE

      Bio-Techne is a United States public company founded in 1976 with 3,100 employees, providing life sciences tools and reagents for research and diagnostics.

      REPLIGEN CORPORATION

      Repligen Corporation is a United States public company founded in 1981 with 2,000 employees, specializing in bioprocess chromatography and filtration technologies.

      GETINGE AB

      Getinge AB is a Swedish public company founded in 1904 with 11,754 employees, manufacturing medical devices and systems for healthcare and life sciences.

      BD

      BD is a United States public company founded in 1897 with 72,000 employees, serving as a global leader in medical technology and diagnostic solutions.

      PERKINELMER INC.

      PerkinElmer Inc. is a United States public company founded in 1937 with 11,000 employees, providing diagnostics, life sciences, and applied services solutions.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Quantified market data for China showing $24M (2024) to $49.4M (2029) trajectory enables accurate business planning, investment decisions, and competitive positioning within Asia's fastest-growing cell expansion market.
      • Regional Growth Drivers Analysis : Detailed insights into China-specific factors—government support, healthcare infrastructure expansion, and manufacturing scale-up—provide actionable intelligence for market entry and localization strategies.
      • Competitive Benchmarking : Understanding China's 15.5% CAGR versus global 13.3% rate reveals market dynamics, competitive intensity, and opportunity gaps for technology providers and manufacturers targeting Chinese biopharmaceutical companies.
      • Investment & Partnership Opportunities : Comprehensive China market data identifies high-growth segments, emerging manufacturers, and strategic partnership opportunities with domestic biotech firms expanding cell therapy capabilities and export ambitions.
      • Regulatory & Operational Insights : China-focused analysis clarifies regulatory pathways, manufacturing standards, and operational requirements essential for successful market entry, product launches, and compliance with Chinese healthcare authorities.

      Frequently asked questions

      What is the current size of China's cell expansion market?

      China's cell expansion market was valued at $24.0 million in 2024 and is projected to reach $49.4 million by 2029.

      What is the growth rate for China's cell expansion market?

      China's cell expansion market is growing at a compound annual growth rate (CAGR) of 15.5% from 2024 to 2029.

      What factors are driving growth in China's cell expansion market?

      Key drivers include government support for biotechnology, increasing investment in regenerative medicine, expanding biomanufacturing capacity, and rising demand for cell therapies in China.

      How does China's cell expansion market compare to global trends?

      China's 15.5% CAGR significantly exceeds the global average of 13.3%, reflecting China's strategic prioritization of cell therapy development and manufacturing.

      What applications are driving cell expansion demand in China?

      Autologous and allogeneic cell therapies, regenerative medicine, personalized medicine, and biopharmaceutical manufacturing are primary applications driving cell expansion technology adoption in China.

      RESEARCH METHODOLOGY

      This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell expansion market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell expansion market. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), US Food and Drug Administration (FDA), South African Medical Research Council, International Society for Cell & Gene Therapy (ISCT), International Business Magazine, Nasdaq, Center for Strategic & International Studies (CSIS), American Society of Gene & Cell Therapy, Statista; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      Extensive primary research was conducted after acquiring basic knowledge about the global cell expansion market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biopharmaceutical companies, research & academic institutes, hospitals & diagnostic laboratories, CROs, and CMOs, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

      The following is a breakdown of the primary respondents:

      Cell Expansion Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell expansion market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Bottom-up Approach

      • The key players in the industry and market have been identified through extensive secondary research
      • The revenues generated from the cell expansion business of leading players have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cell Expansion Market Size, and Share

      To know about the assumptions considered for the study, Request for Free Sample Report

      Top-down Approach

      After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

      Cell Expansion Market Size, and Share

      Data Triangulation

      After arriving at the market size  from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cell expansion is a process of increasing the number of cells through cell division. Cell expansion is often used for research and therapeutic applications. Cell expansion is also used for manufacturing of cell based therapies such as tissue engineering, cell & gene therapy, and regenerative medicine.

      Stakeholders

      • Cell Expansion Product Manufacturers, Vendors, and Distributors
      • Academic and Research Institutes
      • Pharmaceutical and Biotechnology Companies
      • Hospitals and Diagnostic Laboratories
      • Venture Capitalists and Investors
      • Private Research Firms
      • Contract Research Organizations (CROs)
      • Contract Development and Manufacturing Organizations (CDMOs)

      Report Objectives

      • To define, describe, and forecast the global cell expansion market based on the product, cell type, application, end user, and region
      • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities and challenges)
      • To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall cell expansion market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
      • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the cell expansion market.

      Available Customizations

      With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

      Portfolio Assessment

      • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

      Company Information

      • Detailed analysis and profiling of additional market players (up to three).

      Geographical Analysis

      • A further breakdown of the Rest of Asia Pacific cell expansion market into countries
      • A further breakdown of the Rest of Europe  cell expansion market into countries
      • A further breakdown of the Rest of Latin American cell expansion market into countries
      • A further breakdown of the Rest of Middle East cell expansion market into countries

      Get the Full Cell Expansion Market Report

      Full forecast, segment splits, and company analysis for all Cell Expansion Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status